Physician profile
Andrew Charles Von Eschenbach
NPI 1942540190
$3,230,611.24
in general payments reported to CMS, 2019-2025
6 companies · $368K in 2025
The $368K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457K · 2020: $622K · 2021: $571K · 2022: $492K · 2023: $359K · 2024: $362K · 2025: $368K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.0M · Travel and Lodging: $29K · Consulting Fee: $28K · Food and Beverage: $4,882 · Gift: $77.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,026,920.93 |
| Travel and Lodging | $29,111.18 |
| Consulting Fee | $28,198.46 |
| Food and Beverage | $4,881.65 |
| Gift | $77.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,329,666.06 | 2022-2025 | |
| Bausch Health US, LLC | $814,372.78 | 2019-2021 | |
| Radius Health, INC. | $516,294.26 | 2021-2022 | |
| Celularity INC. | $379,842.73 | 2019-2022 | |
| Chugai Pharmaceutical Co., Ltd. | $142,521.04 | 2019-2021 | |
| Trisalus Life Sciences, INC. | $47,914.37 | 2023-2025 | Trinav Infusion System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Von Eschenbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.